C5 and paroxysmal nocturnal hemoglobinuria: Monoclonal antibodies that target complement C5 and inhibit the activation of terminal complement activity (C5 inhibitors) are the current standard of care for PNH, where available [14,15], and have been used in clinical and real-world settings for over 20 years [16].